Piemonti L, Keymeulen B, Gillard P, Linn T, et al. Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2022 May 19. doi: 10.1111/dom.14770.
PMID: 35589610